Abstract: Acute myeloid leukemia (AML) harboring nucleophosmin 1 (NPM1) mutations represents a distinct and challenging genetic subtype, accounting for approximately 30% of all AML cases. Despite initial responses to intensive chemotherapy, relapse rates remain high, necessitating the development of novel targeted therapies. Ziftomenib (KO-539) has emerged as a highly promising, orally bioavailable small-molecule inhibitor that targets the menin-KMT2A protein-protein interaction. By disrupting this complex, ziftomenib downregulates the leukemogenic MEIS1-HOXA transcriptional program, lifting the differentiation blockade and inducing apoptosis in NPM1-mutated leukemic blasts. Clinical trials, notably the KOMET series, have demonstrated significant pharmacological activity, with ziftomenib achieving high rates of complete remission and measurable residual disease (MRD) negativity in heavily pretreated relapsed/refractory (R/R) NPM1-mutated AML patients. These results led to its breakthrough therapy designation by the FDA. While ziftomenib exhibits a manageable safety profile, adverse events such as differentiation syndrome (DS) and the emergence of acquired resistance via MEN1 mutations present ongoing clinical challenges. Current research is heavily focused on integrating ziftomenib into combination regimens—such as with venetoclax/azacitidine or intensive 7+3 chemotherapy—to deepen responses, overcome resistance, and serve as a bridge to allogeneic hematopoietic stem cell transplantation. This review comprehensively synthesizes the molecular mechanisms, clinical efficacy, limitations, and future perspectives of ziftomenib in the treatment of NPM1-mutated AML.
1. Introduction
Acute myeloid leukemia (AML) is a biologically heterogeneous neoplasm characterized by the uncontrolled proliferation of clonal hematopoietic stem and progenitor cells, leading to ineffective hematopoiesis [4]. Among the various genetic drivers of AML, mutations in the nucleophosmin 1 (NPM1) gene are particularly prevalent, occurring in approximately 30% of all AML cases [3]. NPM1-mutated (NPM1m) AML shares a critical pathogenetic mechanism with KMT2A-rearranged (KMT2Ar) leukemias: the aberrant activation of the MEIS1-HOXA transcriptional axis [3]. Menin (MEN1), a well-recognized tumor promoter, is essential for sustaining this leukemic transformation through its interaction with KMT2A, which leads to the dysregulation of target genes [1].
Historically, patients with NPM1m AML have been treated with intensive chemotherapy, achieving initial remission in about 80% of cases; however, nearly 50% of these patients experience relapse, which is associated with a dismal prognosis and a median overall survival of just 6.1 months [3]. The discovery of the menin-KMT2A dependency has spurred the development of menin inhibitors (MIs) as a novel class of targeted therapies. Ziftomenib (KO-539) is a potent, once-daily, oral menin inhibitor that has shown remarkable clinical efficacy. In recognition of its potential, ziftomenib received orphan drug designation from the European Medicines Agency (EMA) in January 2024 and breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) in April 2024 for the treatment of relapsed or refractory (R/R) NPM1m AML [1][7].
2. Pharmacological Activity
Ziftomenib has demonstrated robust pharmacological activity both as a monotherapy and in combination regimens across multiple clinical trials, primarily under the KOMET study program.
Monotherapy Efficacy: The phase 1/2 KOMET-001 trial evaluated ziftomenib monotherapy in adults with R/R AML. During the dose-validation phase, 600 mg once daily was established as the recommended phase 2 dose (RP2D) [3][7]. At this dose, ziftomenib exhibited one of the highest activity levels for any monotherapy in heavily pretreated NPM1m patients. The trial reported a complete remission (CR) rate of 35% and an overall response rate (ORR) of 45% among NPM1m AML patients [2][3]. Furthermore, the quality of remission was deep, with 61% to 67% of responders achieving measurable residual disease (MRD) negativity [2][7]. The median duration of response was reported to be 4.6 to 5.1 months [6][7].
Combination Therapies: To enhance efficacy and overcome potential resistance, ziftomenib is being investigated in combination with standard-of-care regimens in the KOMET-007 and KOMET-008 trials. In KOMET-007, ziftomenib combined with venetoclax and azacitidine in R/R NPM1m AML yielded an ORR of 68% and a composite CR (CRc) of 50% [3][9]. Notably, responses were observed even in patients previously exposed to venetoclax, suggesting ziftomenib can resensitize leukemic cells to BCL-2 inhibition [3]. In newly diagnosed NPM1m AML, ziftomenib combined with intensive induction chemotherapy (7+3 regimen) demonstrated exceptional activity, achieving a CRc rate of 94% to 100% without dose-limiting toxicities [2][6].
3. Molecular Mechanism of Action
The molecular hallmark of NPM1-mutated AML is the aberrant cytoplasmic accumulation of the mutant NPM1 protein, which normally shuttles between the nucleus and cytoplasm to regulate ribosome biogenesis and the ARF-p53 pathway [7][9]. Despite this cytoplasmic mislocalization, NPM1m AML cells remain critically dependent on a nuclear protein complex formed by menin and the histone methyltransferase KMT2A (formerly MLL1) [7].
Menin acts as a transcriptional adaptor that binds to KMT2A, driving the aberrant overexpression of the HOX gene cluster (particularly HOXA9) and the MEIS1 transcription factor [3][7]. This MEIS1-HOXA axis enforces a differentiation blockade, maintaining the cells in a highly proliferative, leukemic state [6]. Ziftomenib functions by selectively binding to menin and disrupting the menin-KMT2A protein-protein interaction [4]. This targeted disruption dismantles the oncogenic chromatin-remodeling complex, leading to the rapid downregulation of HOXA9 and MEIS1 [11]. Consequently, the leukemogenic transcriptional program is silenced, which relieves the differentiation arrest and induces terminal differentiation and apoptosis of the AML blasts [1][7].
4. Structure-Activity Relationship (SAR)
Ziftomenib (KO-539) is a rationally designed, orally bioavailable small molecule that specifically targets the binding interface between menin and KMT2A [4]. While detailed structural medicinal chemistry data are limited in the provided literature, it is established that ziftomenib acts as a potent and selective non-covalent inhibitor of this protein-protein interaction [11]. Pharmacokinetically, ziftomenib is metabolized in vivo into at least two active metabolites that possess antileukemic activity comparable to the parent compound itself, contributing to its sustained pharmacological effect with once-daily oral dosing [4].
5. Current Limitations
Despite its promising efficacy, the clinical application of ziftomenib is accompanied by specific limitations, primarily related to adverse events and the emergence of drug resistance.
Adverse Events: The most notable on-target toxicity associated with menin inhibitors is Differentiation Syndrome (DS), which results from the rapid maturation of leukemic blasts. In the KOMET-001 trial, DS occurred in approximately 24% to 25% of patients treated with ziftomenib [6][7]. While potentially life-threatening, DS is generally manageable with prompt recognition and the administration of corticosteroids (e.g., dexamethasone) and hydroxyurea [4][7]. Other common grade 3 or higher treatment-emergent adverse events include cytopenias (anemia, thrombocytopenia, febrile neutropenia) and infections (pneumonia, sepsis) [2][4]. Notably, compared to other menin inhibitors like revumenib, ziftomenib has shown a lower incidence of clinically significant QTc prolongation, with most cases resolving upon electrolyte repletion or adjustment of concomitant medications [2][6].
Resistance Mechanisms: Acquired resistance to menin inhibitors frequently emerges during monotherapy. The primary genetic mechanism involves somatic missense mutations in the MEN1 gene at the drug-binding pocket. These mutations disrupt the binding of ziftomenib while preserving the menin-KMT2A interaction, thereby sustaining the leukemogenic HOX/MEIS1 program [7][11]. Additionally, non-genetic resistance mechanisms driven by epigenetic plasticity—such as alterations in the KMT2C/D-UTX complex or Polycomb repressive machinery—can reactivate oncogenic pathways (e.g., MYC) independently of menin inhibition [11].
6. Future Perspectives
The future clinical development of ziftomenib is focused on moving the drug into earlier lines of therapy and utilizing rational combinations to maximize efficacy and prevent resistance.
Combination Strategies: To overcome resistance and deepen remissions, ziftomenib is being integrated with other targeted agents. Preclinical data demonstrate strong synergy between ziftomenib and FLT3 inhibitors (e.g., gilteritinib) for patients with co-mutated NPM1 and FLT3, as menin inhibition downregulates FLT3 transcription [1][4]. Similarly, combinations with XPO1 inhibitors (e.g., selinexor) are being explored, as XPO1 mediates the abnormal cytoplasmic displacement of mutant NPM1 [1]. Clinical trials (KOMET-007 and KOMET-008) are actively evaluating ziftomenib alongside venetoclax/azacitidine and intensive chemotherapy, showing highly promising preliminary response rates [3][9].
Bridge to Transplant and Maintenance: Ziftomenib has proven to be a valuable bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT) for heavily pretreated patients. A significant proportion of responders in clinical trials have successfully proceeded to allo-HSCT, and ziftomenib is currently being evaluated as a post-transplant maintenance therapy to prevent relapse [3][7].
Frontline Therapy: Based on its success in the R/R setting, ziftomenib is advancing into frontline trials. The ongoing phase III KOMET-017 trial will evaluate its efficacy as a first-line treatment for newly diagnosed NPM1m AML [2][11]. Continued biomarker-driven research will be essential to define the optimal sequencing and combinatorial use of ziftomenib, ultimately aiming to redefine the treatment paradigm and improve long-term survival for patients with NPM1-mutated AML [3][10].
